Search Results
Oct 17, 2025, 10:00 ET Boehringer's HERNEXEOS® demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
About non-small cell lung cancer (NSCLC)Lung cancer claims more lives than any other cancer type4 and the incidence is set to increase to over 3 million cases worldwide by 2040.5 NSCLC is the most common type of lung cancer.4 The condition is
More news about: Boehringer Ingelheim
Oct 17, 2025, 10:00 ET SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
ongoing registrational studies across lung, breast, and urothelial cancers." About the BL-B01D1-LUNG-101 Phase I clinical trial BL-B01D1-LUNG-101 (NCT05983432) is a global, multi-center,
More news about: SystImmune, Inc.
Oct 17, 2025, 10:00 ET Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
e-ongoing-first-in-human-study-evaluating-its-cd44v9-directed-antibody-drug-conjugate-amt-116-in-heavily-pretreated-egfr-wild-type-non-small-cell-lung--302587390.html SOURCE Multitude Therapeutics, Inc.
More news about: Multitude Therapeutics, Inc.
Oct 17, 2025, 09:50 ET Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
blood cancers, the company is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and prostate cancers. GT Biopharma plans to
More news about: Equity Insider
Oct 17, 2025, 09:00 ET Precision Oncology Approaches Drive $312B Market Transformation
blood cancers, the company is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and prostate cancers. GT Biopharma plans to
More news about: USA News Group
Oct 17, 2025, 08:00 ET Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at ESMO 2025
20.5% ORR and 79% DCR observed in heavily pretreated TMB-H or MSI-H/dMMR tumors across six major solid tumor types, including colorectal, lung, breast, gastric, GEJ, and head and neck cancers
More news about: Marengo Therapeutics
Oct 17, 2025, 08:00 ET Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
About Breast Cancer Breast cancer is the second most commonly diagnosed cancer worldwide (following lung cancer), according to GLOBOCAN. The estimated 2.3 million new cases indicate that close to 1 in every 4 cancers diagnosed in 2022 is breast cancer.
More news about: Eli Lilly and Company
Oct 17, 2025, 07:00 ET CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
Bronchiectasis NCFB is a serious, chronic, and progressive inflammatory lung disease in which the bronchi become permanently dilated due to a cycle of infection, inflammation, lung tissue damage and mucociliary dysfunction. The disease is marked by frequent pulmonary exacerbations
More news about: Insmed Incorporated
Oct 16, 2025, 23:13 ET Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization
by Fosun, as an example to illustrate Fosun's approach to innovation. Lung cancer has the highest morbidity and mortality rates among all malignancies in the world, and small cell lung cancer (SCLC) is the most aggressive subtype. Approximately 80% of SCLC patients are already
More news about: Fosun
Oct 16, 2025, 15:40 ET NYU Langone Health Rated Top-Quality Kidney, Liver & Lung Transplant Programs in New York
lung transplants in adults. The lung transplant program has the highest one-year organ survival rate in New York State and gets deceased donor organs to recipients on
More news about: NYU Langone Health
Oct 16, 2025, 13:08 ET Eon Further Establishes Leadership Position in Early Detection and Management of Incidental Findings, Announces Half a Billion Radiology Reports Analyzed
patient with Stage IV lung cancer whose incidental finding had been missed, Eon launched its first lung AI in 2016. Built on proprietary computational linguistics—an AI approach that provides consistent, traceable results—the company has developed specialized AI engines across lung, pancreas, breast, thyroid,
More news about: Eon
Oct 16, 2025, 10:30 ET Anvisa aprova nova indicação para durvalumabe da AstraZeneca que reduz em 32% o risco de recidiva no câncer de pulmão operável[1]
Lab Med. 2013;137(9):1191-1198.[6-7] Goldstraw P, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51; [8] AstraZeneca. Imfinzi
More news about: AstraZeneca
Oct 16, 2025, 08:05 ET Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates
More news about: Pulmatrix Inc.
Oct 16, 2025, 07:00 ET Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
Bronchiectasis Bronchiectasis is a serious, chronic lung disease in which the bronchi become permanently dilated due to a cycle of infection, inflammation, and lung tissue damage. The condition is marked by frequent pulmonary exacerbations requiring antibiotic
More news about: Insmed Incorporated
Oct 16, 2025, 06:12 ET The Galien Foundation Hosts 2025 Patient Summit to Amplify the Patient Voice in Healthcare
Nordisk Swee Lay Thein, MD – Senior Investigator and Branch Chief - Sickle Cell Branch - National Heart, Lung and Blood Institute / National Institutes of Health Patient speaker to be confirmed
More news about: The Galien Foundation
Oct 16, 2025, 04:01 ET SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
progress that has been made in clinical care in recent years, especially in the context of pre-surgical immunotherapy for patients with non-small cell lung cancer eligible for surgery. I truly believe that it is the future of data-driven medicine." Powered by state-of-the-art artificial
More news about: SOPHiA GENETICS
Oct 16, 2025, 04:01 ET SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
progress that has been made in clinical care in recent years, especially in the context of pre-surgical immunotherapy for patients with non-small cell lung cancer eligible for surgery. I truly believe that it is the future of data-driven medicine." Powered by state-of-the-art artificial
More news about: SOPHiA GENETICS
Oct 16, 2025, 00:15 ET HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and Selected for ESMO 2025 LBA Presentation
PD-1/VEGF bispecific antibody, combined with chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). The article of Lancet will be simultaneously published during the 2025 European Society for Medical Oncology (2025 ESMO) Congress.
More news about: Akeso, Inc.
Oct 15, 2025, 17:03 ET WILLIAM SHATNER CALLS ON GLOBAL HEALTH ADVOCATES TO UNITE AROUND AFFORDABLE, REAL-TIME DIAGNOSTICS FOR CANCER
achieved a landmark validation: the detection of the three key EGFR mutations that drive non-small cell lung cancer (NSCLC) – L858R, Exon 19 deletions and T790M. NSCLC accounts for nearly 85 percent of lung cancer cases and remains the leading cause of cancer death worldwide, making rapid, precise EGFR detection
More news about: IdentifySensors Biologics
Oct 15, 2025, 16:05 ET TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2025 after market close on Wednesday, October
More news about: TransMedics Group, Inc.
Oct 15, 2025, 13:00 ET OCTOBER IS BREAST CANCER AWARENESS MONTH: PROCURE URGES WOMEN TO PRIORITIZE EARLY SCREENINGS, UNDERSTAND TREATMENT OPTIONS
opened in March 2012 as the tri-state region's first proton therapy facility, treating a range of cancers including diseases of the prostate, breast, lung, brain, head and neck, and gastrointestinal system, as well as sarcomas and many pediatric cases. Using the most advanced radiation treatment available,
More news about: ProCure Proton Therapy Center
Oct 15, 2025, 12:44 ET Florida Cancer Specialists & Research Institute Champions the Impact of Integrated Oncology At NCODA International Summit
NSCLC, Colorectal, Breast and Prostate Cancers, highlighting the necessity of liquid and tissue next-generation sequencing, particularly when treating lung, colorectal, breast and prostate cancers.
More news about: Florida Cancer Specialists & Research Institute
Oct 15, 2025, 12:00 ET Lapsi Health Unveils Keikku 2.0: World's First FDA-Cleared Digital Stethoscope with Integrated AI Scribe
Beyond documentation, Keikku 2.0 supports clinical decision-making. Its multiple sensors and AI-powered auscultation analytics detect cardiac murmurs and lung sounds that may indicate disease, giving clinicians immediate, data-driven insights during routine exams. By turning sound into structured data, Keikku
More news about: Lapsi Health
Oct 15, 2025, 11:50 ET Taiwan Launches 2025 "Taiwan Weeks" to Advance its Position as Asian Asset Management Center
management center in Asia. The two-week program was opened by the Financial Supervisory Commission (FSC) Chairman Peng Jin-lung and attracted participation from over 150 listed companies, more than 100 financial institutions, and nearly 80 representatives from global exchanges
More news about: TWSE
Oct 15, 2025, 11:12 ET Taiwan Launches 2025 "Taiwan Weeks" to Advance its Position as Asian Asset Management Center
management center in Asia. The two-week program was opened by the Financial Supervisory Commission (FSC) Chairman Peng Jin-lung and attracted participation from over 150 listed companies, more than 100 financial institutions, and nearly 80 representatives from global exchanges
More news about: TWSE